GEMEINNUTZIGE SALZBURGER LANDESKLINIKEN BETRIEBSGESELLSCHAFT

Their core work

SALK (Salzburger Landeskliniken) is one of Austria's largest public hospital groups, operating the main university hospital complex in Salzburg. In the H2020 context, they contribute as a clinical research site — providing patient access, translational oncology capacity, and clinical expertise to European research consortia. Their two projects reveal a dual focus: participation in a Marie Curie training network on mitochondrial mechanisms in cancer, and third-party involvement in the large European Joint Programme on Rare Diseases, where they support data sharing, patient empowerment, and translational pathways from bench to bedside.

What they specialise in

How they've shifted over time

SALK's earliest H2020 engagement (2017) was in fundamental translational research — specifically the molecular biology of cancer through the lens of mitochondrial function, within a structured doctoral training programme. By 2019, their focus had broadened significantly toward rare disease ecosystems: patient empowerment, multi-partner data sharing, FAIR data principles, omics integration, and public-private partnerships in clinical research. This shift suggests SALK is moving from a narrow specialist contributor in oncology toward a hospital partner embedded in large-scale clinical research infrastructure programmes.

SALK appears to be deepening its role in rare disease research networks and clinical data infrastructure, making them a relevant partner for future consortia focused on patient registries, omics-based diagnostics, or translational rare disease pipelines.

How they like to work

SALK has not held a coordinator role in any H2020 project — they join as participant or third party, consistent with how major hospital groups typically engage: contributing clinical infrastructure rather than driving project management. Their network of 162 unique partners across 35 countries is exceptionally large relative to just two projects, reflecting involvement in the EJP RD mega-consortium which spans hundreds of institutions. This suggests SALK is comfortable operating within large, federated research structures where their value is clinical access and site expertise.

SALK is connected to 162 unique consortium partners across 35 countries — an unusually broad network for an organisation with only two funded projects, entirely explained by EJP RD's scale as one of Europe's largest rare disease research programmes. No geographic concentration is apparent beyond the European scope.

What sets them apart

SALK is a large public hospital group rather than a pure research institute, which means it offers something most academic partners cannot: direct access to clinical infrastructure, real patient populations, and the regulatory environment of routine hospital care. For consortium builders who need a credible clinical validation site in the German-speaking Alpine region of central Europe, SALK fills a role that universities and research centres cannot replicate. Their presence in both a molecular oncology training network and a rare disease joint programme signals genuine cross-disease clinical breadth.

Highlights from their portfolio

• TRANSMIT
  SALK's only directly funded H2020 project (EUR 255,934), embedding the hospital as a training site in a Marie Curie doctoral network on mitochondrial mechanisms in cancer — an unusual molecular-biology role for a clinical institution.
• EJP RD
  One of the largest rare disease research programmes in Europe (COFUND-EJP scheme, 2019–2024), connecting SALK to over 130 partners across 35 countries and establishing their presence in rare disease data sharing and patient empowerment work.